Literature DB >> 28162004

Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.

Douglas V N P Oliveira1, Shanshan Zhang2, Xin Chen2, Diego F Calvisi3, Jesper B Andersen1.   

Abstract

INTRODUCTION: Intrahepatic cholangiocarcinoma (iCCA) is the second most frequent primary tumor of the liver and a highly lethal disease. Therapeutic options for advanced iCCA are limited and ineffective due to the largely incomplete understanding of the molecular pathogenesis of this deadly tumor. Areas covered: The present review article outlines the main studies and resulting discoveries on the molecular profiling of iCCA, with a special emphasis on the different techniques used for this purpose, the diagnostic and prognostic markers identified, as well as the genes and pathways that could be potentially targeted with innovative therapies. Expert commentary: Molecular profiling has led to the identification of distinct iCCA subtypes, characterized by peculiar genetic alterations and transcriptomic features. Targeted therapies against some of the identified genes are ongoing and hold great promise to improve the prognosis of iCCA patients.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma (iCCA); molecular profiling; precision medicine; signaling pathways; therapeutic targets

Mesh:

Substances:

Year:  2017        PMID: 28162004     DOI: 10.1080/17474124.2017.1292127

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  6 in total

1.  Characterization and prognostic significance of mortalin, Bcl-2 and Bax in intrahepatic cholangiocarcinoma.

Authors:  Qiang Kang; Hao Zou; Xuan Yang; Jia-Bin Cai; Li-Xin Liu; Nan Xie; Lian-Min Wang; Yue-Hua Li; Xiao-Wen Zhang
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

2.  Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.

Authors:  Ningjia Shen; Dadong Zhang; Lei Yin; Yinghe Qiu; Jian Liu; Wenlong Yu; Xiaohui Fu; Bin Zhu; Xiaoya Xu; Anqi Duan; Zishuo Chen; Xiang Wang; Xinkai Cao; Teng Zhao; Zisong Zhou; Lianghe Yu; Hao Qin; Zheng Fang; Jing-Yu Li; Yuanjin Liu; Lei Xiong; Bo Yuan; Fugen Li; Yongjie Zhang
Journal:  Oncol Rep       Date:  2019-05-31       Impact factor: 3.906

3.  The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma.

Authors:  Hua Yu; Han Wang; Wei Dong; Zhen-Ying Cao; Rong Li; Chao Yang; Wen-Ming Cong; Hui Dong; Guang-Zhi Jin
Journal:  PeerJ       Date:  2020-01-27       Impact factor: 2.984

Review 4.  Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma.

Authors:  Brinda Balasubramanian; Simran Venkatraman; Kyaw Zwar Myint; Tavan Janvilisri; Kanokpan Wongprasert; Supeecha Kumkate; David O Bates; Rutaiwan Tohtong
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-11

Review 5.  New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.

Authors:  Maria Consiglia Bragazzi; Lorenzo Ridola; Samira Safarikia; Sabina Di Matteo; Daniele Costantini; Lorenzo Nevi; Vincenzo Cardinale
Journal:  Ann Gastroenterol       Date:  2017-11-02

Review 6.  Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma.

Authors:  Clifford Akateh; Aslam M Ejaz; Timothy Michael Pawlik; Jordan M Cloyd
Journal:  World J Hepatol       Date:  2020-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.